Inogen reported strong international revenue growth of 15% year-over-year in Q2 2026, marking its 10th consecutive quarter of double-digit international growth. The company's core portable oxygen concentrator unit volume grew over 12%, outpacing overall market growth. Gross margin expanded by 65 basis points to 45.6%, driven by cost improvements and lower warranty expenses. Inogen raised its full-year adjusted EBITDA guidance to approximately $4 million, representing 48% growth over 2025. However, the company lowered its full-year revenue guidance to $355–361 million from $366–373 million. US sales declined 2% year-over-year due to channel mix challenges, whilst US rental revenue decreased 12%. New products Voxy and Aurora are gaining traction, with Voxy shipping over 5,000 units. Inogen maintains a strong balance sheet with $106.8 million in cash and no debt.

Yuwell Medical has announced a strategic investment in Inogen, a US-based respiratory health company. Through its Hong Kong subsidiary, Yuwell will invest approximately $27.2 million for a 9.9% stake in Inogen's common stock. The partnership will focus on four key areas: international distribution, trademark licensing, joint research and development, and supply chain optimisation. Both companies specialise in oxygen concentrators and aim to combine their expertise across different markets. At Yuwell's 2025 Global Core Partner Conference, Chairman Alex Wu outlined the company's five-year vision to become one of the top three global players in home medical health. Yuwell identified respiratory treatment solutions, diabetes care, and emergency services as its three strategic priorities for international expansion.

Inogen, a medical technology company specialising in respiratory products, has appointed Andy Reding as Chief Operating Officer, effective 6 July 2026. Reding will oversee revenue and operational performance whilst aligning cross-functional priorities as the company pursues new product launches and geographic expansion. Reding brings over 30 years of experience in medical technology. Most recently, he served as Chief Commercial Officer at Viant Medical for six years, where he led teams across 25 facilities. He previously held leadership roles at Hillrom Respiratory Health, managing sales, marketing and product development. As part of his employment, Reding will receive 130,000 restricted stock units vesting over three years. He holds an MBA from the University of South Carolina and a bachelor's degree from Marquette University.